HEPA Quote, Financials, Valuation and Earnings

Fortress Biotech has a net margin of -- compared to Hepion Pharmaceuticals's net margin of -80.55%. Hepion Pharmaceuticals's return on equity of -- beat Fortress Biotech's return on equity of --.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2112576.06%. On the other hand Fortress Biotech has an analysts' consensus of $10.00 which suggests that it could grow by 446.45%. Given that Hepion Pharmaceuticals has higher upside potential than Fortress Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Fortress Biotech.

Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.853, suggesting its more volatile than the S&P 500 by 85.291%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Fortress Biotech quarterly revenues of $13.1M. Hepion Pharmaceuticals's net income of -$6.1M is higher than Fortress Biotech's net income of -$10.6M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.72x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 40.52%. Hepion Pharmaceuticals's return on equity of -- beat Krystal Biotech's return on equity of 13.91%.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2112576.06%. On the other hand Krystal Biotech has an analysts' consensus of $205.20 which suggests that it could grow by 62.28%. Given that Hepion Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Krystal Biotech.

Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.292%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $88.2M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Krystal Biotech's net income of $35.7M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 30.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 11.32x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Protagenic Therapeutics has a net margin of -- compared to Hepion Pharmaceuticals's net margin of --. Hepion Pharmaceuticals's return on equity of -- beat Protagenic Therapeutics's return on equity of --.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2112576.06%. On the other hand Protagenic Therapeutics has an analysts' consensus of -- which suggests that it could grow by 5585.28%. Given that Hepion Pharmaceuticals has higher upside potential than Protagenic Therapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Protagenic Therapeutics.

Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Protagenic Therapeutics has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.318%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagenic Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Protagenic Therapeutics pays out -- of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Protagenic Therapeutics quarterly revenues of --. Hepion Pharmaceuticals's net income of -$6.1M is lower than Protagenic Therapeutics's net income of -$1.4M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Protagenic Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.13x for Protagenic Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 21.46%. Hepion Pharmaceuticals's return on equity of -- beat Rigel Pharmaceuticals's return on equity of --.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2112576.06%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 71.98%. Given that Hepion Pharmaceuticals has higher upside potential than Rigel Pharmaceuticals, analysts believe Hepion Pharmaceuticals is more attractive than Rigel Pharmaceuticals.

Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.678%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Rigel Pharmaceuticals quarterly revenues of $53.3M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Rigel Pharmaceuticals's net income of $11.4M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Rigel Pharmaceuticals's PE ratio is 9.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 1.72x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.